Last updated: 11/07/2018 18:50:25
A multi-centre study examining the use of salmeterol xinafoate / fluticasone propionate via Diskus in relation to controlling asthma in moderate to severe patients: identifying risk factors contributing to an exacerbation of asthma and modification of treatment during exacerbations.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multi-centre study examining the use of salmeterol xinafoate / fluticasone propionate via Diskus in relation to controlling asthma in moderate to severe patients: identifying risk factors contributing to an exacerbation of asthma and modification of treatment during exacerbations.
Trial description: A multi-centre study examining the use of salmeterol xinafoate / fluticasone propionate via Diskus in relation to controlling asthma in moderate to severe patients: identifying risk factors contributing to an exacerbation of asthma and modification of treatment during exacerbations.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Schreurs et al: A multi-centre double blind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate / fluticasone propionate product versus prednisolone. Eur. Resp. J. 2003; 22: Suppl. 45, 287s.
Schreurs et al: Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate / fluticasone propionate. Eur. Resp. J. 2003; 22: Suppl. 45, 287s.
Medical condition
Asthma
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
June 1999 to March 2002
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2002-01-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website